RxDoctor Payments Data

Victor Abrich, MD

Clinical Cardiac Electrophysiology · Waterloo, IANPI 1336428697

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (55.6%), food and beverage and grants — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Medtronic at 40.6% of the total.

$47,143in general payments, 2019–2025

Across 396 payments — averaging $119.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$19K
  • Biotronik Inc.$10K
  • Boston Scientific$8K
  • Abbott$5K
  • Biosense Webster, Inc.$2K
  • Medical Device Business Services, Inc.$959
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$4751%
  • Grants$1,4003%
  • Travel & lodging$26,19356%
  • Food & beverage$19,00840%
  • Education$670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,143 in reported general payments places this provider in the 80th percentile of 42 clinical cardiac electrophysiology providers in Iowa.

See all clinical cardiac electrophysiology providers in Iowa

Medicare billing

Part B allowed, 2024
$323,977
Medicare patients
1,235
Services billed
5,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban513$435,847
EntrestoSacubitril/Valsartan159$134,122
XareltoRivaroxaban109$92,555
MultaqDronedarone Hcl39$43,913
JardianceEmpagliflozin36$24,380
CorlanorIvabradine Hcl19$10,956
Dofetilide47$7,314
FarxigaDapagliflozin Propanediol12$6,889
Bumetanide259$6,514
Metoprolol Succinate604$5,763
SotalolSotalol Hcl499$5,718
Flecainide Acetate179$5,355
Diltiazem 24hr Er (Cd)Diltiazem Hcl311$5,005
Propafenone Hcl ErPropafenone Hcl22$4,562
Midodrine Hcl38$3,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$94$435,847513 claims
NovartisEntresto$251$134,122159 claims
Johnson & JohnsonXarelto$29$92,555109 claims
Boehringer IngelheimJardiance$80$24,38036 claims
AmgenCorlanor$30$10,95619 claims
AstraZenecaFarxiga$14$6,88912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 42 clinical cardiac electrophysiology providers in Iowa.

Other clinical cardiac electrophysiology in Waterloo

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →